[{"id":"cab3b137-c452-48a2-a45f-fa993e3403a2","acronym":"CD7-CAR01","url":"https://clinicaltrials.gov/study/NCT06064903","created_at":"2023-10-03T19:11:26.359Z","updated_at":"2024-07-02T16:35:00.577Z","phase":"Phase 1/2","brief_title":"CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL","source_id_and_acronym":"NCT06064903 - CD7-CAR01","lead_sponsor":"Bambino Gesù Hospital and Research Institute","biomarkers":" CD7","pipe":" | ","alterations":" CD7 expression","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 04/21/2024","start_date":" 04/21/2024","primary_txt":" Primary completion: 09/30/2028","primary_completion_date":" 09/30/2028","study_txt":" Completion: 09/30/2040","study_completion_date":" 09/30/2040","last_update_posted":"2024-05-29"},{"id":"6874df97-e833-4a9e-bd15-5cc442d40050","acronym":"","url":"https://clinicaltrials.gov/study/NCT05377827","created_at":"2022-05-17T11:53:47.550Z","updated_at":"2024-07-02T16:35:33.726Z","phase":"Phase 1","brief_title":"Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies","source_id_and_acronym":"NCT05377827","lead_sponsor":"Washington University School of Medicine","biomarkers":" CD7","pipe":" | ","alterations":" CD7 expression","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e soficabtagene geleucel (WU CART 007)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 10/10/2023","start_date":" 10/10/2023","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2023-10-12"},{"id":"f023df74-8e41-4cbc-9129-d952653453b9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04916860","created_at":"2021-06-08T15:52:26.751Z","updated_at":"2024-07-02T16:35:51.823Z","phase":"","brief_title":"Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","source_id_and_acronym":"NCT04916860","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" IL6 • IL10 • CD7","pipe":" | ","alterations":" CD7 expression","tags":["IL6 • IL10 • CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SENL101"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 01/27/2021","start_date":" 01/27/2021","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 03/31/2023","study_completion_date":" 03/31/2023","last_update_posted":"2023-03-31"},{"id":"d4fac740-1c04-4ba5-ad4f-34acb9f47e6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05626400","created_at":"2022-11-23T14:57:15.756Z","updated_at":"2024-07-02T16:35:59.974Z","phase":"","brief_title":"Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL","source_id_and_acronym":"NCT05626400","lead_sponsor":"Hebei Senlang Biotechnology Inc., Ltd.","biomarkers":" CD7","pipe":" | ","alterations":" CD7 expression","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SENL101"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/29/2022","start_date":" 08/29/2022","primary_txt":" Primary completion: 10/30/2027","primary_completion_date":" 10/30/2027","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2022-11-24"},{"id":"e5c5eae6-8509-4755-adc9-bf7f4b92692e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04785833","created_at":"2021-03-08T13:56:36.619Z","updated_at":"2024-07-02T16:36:33.656Z","phase":"","brief_title":"CD7 CAR-T in the Treatment of CD7 Positive Refractory Relapsed Acute Leukemia","source_id_and_acronym":"NCT04785833","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" CD7","pipe":" | ","alterations":" CD7 expression","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PA3-17"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/04/2021","start_date":" 03/04/2021","primary_txt":" Primary completion: 04/30/2022","primary_completion_date":" 04/30/2022","study_txt":" Completion: 02/04/2024","study_completion_date":" 02/04/2024","last_update_posted":"2021-03-08"},{"id":"4e098aa7-e645-4938-b6f3-f761ea81d884","acronym":"","url":"https://clinicaltrials.gov/study/NCT04004637","created_at":"2021-01-18T19:40:47.452Z","updated_at":"2024-07-02T16:36:40.642Z","phase":"Phase 1","brief_title":"CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia","source_id_and_acronym":"NCT04004637","lead_sponsor":"PersonGen BioTherapeutics (Suzhou) Co., Ltd.","biomarkers":" CD7","pipe":" | ","alterations":" CD7 expression","tags":["CD7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • PA3-17"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 08/25/2019","start_date":" 08/25/2019","primary_txt":" Primary completion: 06/01/2021","primary_completion_date":" 06/01/2021","study_txt":" Completion: 06/01/2021","study_completion_date":" 06/01/2021","last_update_posted":"2020-09-28"}]